MX2022008099A - Tratamiento para el cancer con inhibidores de cdk12/13. - Google Patents

Tratamiento para el cancer con inhibidores de cdk12/13.

Info

Publication number
MX2022008099A
MX2022008099A MX2022008099A MX2022008099A MX2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A
Authority
MX
Mexico
Prior art keywords
cancer
cdk12
inhibitors
treatment
compositions
Prior art date
Application number
MX2022008099A
Other languages
English (en)
Inventor
Elisabeth Gardiner
Eric A Murphy
Toufike Kanouni
Eric Martin
John Tyhonas
Lee D Arnold
Noelito Timple
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of MX2022008099A publication Critical patent/MX2022008099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan composiciones y métodos para el tratamiento de cáncer de mama triple negativo, cáncer de ovario y cáncer de próstata resistente a la castración. Dichas composiciones comprenden inhibidores de CDK12/13.
MX2022008099A 2019-12-31 2020-12-23 Tratamiento para el cancer con inhibidores de cdk12/13. MX2022008099A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962956114P 2019-12-31 2019-12-31
PCT/US2020/066967 WO2021138215A1 (en) 2019-12-31 2020-12-23 Treatment of cancer with cdk12/13 inhibitors

Publications (1)

Publication Number Publication Date
MX2022008099A true MX2022008099A (es) 2022-07-11

Family

ID=76686778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008099A MX2022008099A (es) 2019-12-31 2020-12-23 Tratamiento para el cancer con inhibidores de cdk12/13.

Country Status (11)

Country Link
US (1) US20230074545A1 (es)
EP (1) EP4085053A4 (es)
JP (1) JP2023508996A (es)
KR (1) KR20220123064A (es)
CN (1) CN115175899A (es)
AU (1) AU2020417223A1 (es)
BR (1) BR112022012867A2 (es)
CA (1) CA3166386A1 (es)
IL (1) IL294392A (es)
MX (1) MX2022008099A (es)
WO (1) WO2021138215A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
AU2019291935A1 (en) 2018-06-29 2021-02-04 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
US20230203010A1 (en) * 2021-12-03 2023-06-29 Incyte Corporation Bicyclic amine cdk12 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2024032561A1 (en) * 2022-08-08 2024-02-15 Insilico Medicine Ip Limited Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof
WO2024175065A1 (zh) * 2023-02-24 2024-08-29 中国科学院上海有机化学研究所 一类含有芳基取代的cdk12/13的降解剂，及其制备方法、药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20160264552A1 (en) * 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of prolferative diseases
EP3787629A4 (en) * 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
AU2019291935A1 (en) * 2018-06-29 2021-02-04 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases

Also Published As

Publication number Publication date
CA3166386A1 (en) 2021-07-08
JP2023508996A (ja) 2023-03-06
KR20220123064A (ko) 2022-09-05
BR112022012867A2 (pt) 2022-09-06
US20230074545A1 (en) 2023-03-09
EP4085053A4 (en) 2023-12-27
CN115175899A (zh) 2022-10-11
EP4085053A1 (en) 2022-11-09
WO2021138215A1 (en) 2021-07-08
AU2020417223A1 (en) 2022-07-14
IL294392A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551923A1 (en) Methods and compositions for treating cancer
NZ754865A (en) Combination therapy for the treatment of cancer
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
EP4317422A3 (en) Combinatorial cancer immunotherapy
MX2019003938A (es) Compuestos espirociclicos.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
TN2019000211A1 (en) Antitumoral compounds
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2017012553A (es) Compuestos espirociclicos.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2023012515A (es) Tratamiento del cancer con un inhibidor de raf.
WO2018193476A3 (en) ANTICANCER COMPOUNDS